Achieved 26% year-over-year net product sales growth in Q1 2026, driven by strong performance in TAVALISSE and REZLIDHIA despite typical seasonal reimbursement headwinds. Transitioned from a single-product company in 2020 to a diversified commercial entity with three products approved across four indications, supported by a $146.7 million cash position. Attributed TAVALISSE growth of 31% to increased demand and favorable gross-to-net dynamics compared to the prior year period. Focused on a 'transfor ...